News

Recently, EuCARE research was featured at EBMLive 2026 in Oxford through two oral presentations showcasing studies developed within the consortium. Giulia Doi presented a meta-analysis on the prevalence of anxiety, depression and distress among cancer patients during the COVID-19 pandemic. The study was selected for the conference’s Plenary Session under the Enhancing Evidence for Public […]

Another successful edition of the European Meeting on HIV & Hepatitis (Barcelona, Spain) has come to an end. As an EMHH 2026 Endorser, EuCARE was proud to support a meeting that continues to bring together researchers, clinicians and healthcare professionals to discuss the latest developments in infectious diseases and antiviral research. The event also provided

🦠 SARS-CoV-2 and Ebola virus are both zoonotic pathogens, but they differ significantly in how they spread, the disease they cause and their public health impact. While SARS-CoV-2 led to a global pandemic due to its highly efficient human-to-human transmission, Ebola outbreaks are typically more localized. Understanding the rationale for these differences is essential for

The 24th European Meeting on HIV & Hepatitis (EMHH 2026) will take place in Barcelona, Spain, from 10–12 June 2026. Bringing together clinicians, researchers and healthcare professionals, EMHH provides a platform to discuss the latest developments in HIV and hepatitis research, antiviral therapies and clinical practice. EuCARE will be there, contributing to the exchange of

ANDV prevention strategies focus mainly on environmental safety and infection control. 🔬 Key measures include rodent control, ventilation of contaminated spaces, wet-cleaning methods to avoid aerosolization, surface disinfection and PPE use by healthcare workers. Although rare, person-to-person transmission has been reported, meaning isolation of infected individuals may sometimes be necessary. Unlike SARS-CoV-2, no vaccine is

On May 18th, Camilla Tincati, MD, PhD, Associate Professor at the University of Milan, presented a scientific talk on Long COVID at the Massachusetts Consortium on Pathogen Readiness (MassCPR) at Harvard Medical School. The presentation, entitled “Clinical and Viro-Immunological Determinants of Long COVID: A Journey from the First Wave in Italy to the Biology of

This is the first post in our series comparing key characteristics of SARS-CoV-2 and ANDV. 🌍 Understanding how viruses spread is essential for public health preparedness. 🔬 While SARS-CoV-2 spreads efficiently from person to person, Andes virus (ANDV) follows a very different transmission pattern. ANDV is primarily transmitted from rodents to humans through exposure to contaminated

Once again the AREVIR meeting brought together an international community of researchers to share insights, challenge perspectives, and advance the understanding of viral infections . Across the day, the programme highlighted key topics shaping current research, from viral dynamics and immune responses to emerging challenges in infectious diseases and public health. The EuCARE /VIROMARKERS session

The AREVIR Meeting 2026 is almost here, and this year features a special joint session with the EuCARE and VIROMARKERS projects! Join us for presentations by leading scientists, sharing preliminary activities, current findings, and future steps to tackle evolving challenges in infectious diseases. 🗓 Date: April 24, 2026📍 Location: Cologne, Germany Check out the agenda

We’re launching a new series of short testimonials from the people behind the project. Researchers, clinicians, and partners across Europe and beyond, sharing what EuCARE represents to them. We start with the team from Pomeranian Medical University, reflecting on collaboration, science, and the shared mission that connects us. For the Portuguese team, EuCARE means collaboration,